Janux Therapeutics, Inc. (JANX): Price and Financial Metrics
JANX Price/Volume Stats
| Current price | $26.21 | 52-week high | $71.71 |
| Prev. close | $24.76 | 52-week low | $22.48 |
| Day low | $25.01 | Volume | 609,347 |
| Day high | $26.88 | Avg. volume | 1,009,118 |
| 50-day MA | $27.19 | Dividend yield | N/A |
| 200-day MA | $41.31 | Market Cap | 1.55B |
JANX Stock Price Chart Interactive Chart >
Janux Therapeutics, Inc. (JANX) Company Bio
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.
JANX Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
JANX Price Returns
| 1-mo | 1.98% |
| 3-mo | -14.46% |
| 6-mo | -59.67% |
| 1-year | -38.46% |
| 3-year | 140.90% |
| 5-year | N/A |
| YTD | -51.05% |
| 2024 | 398.97% |
| 2023 | -18.53% |
| 2022 | -33.25% |
| 2021 | N/A |
| 2020 | N/A |